Cardica, Inc.  

(Public, NASDAQ:CRDC)   Watch this stock  
Find more results for CRDC
-0.010 (-2.78%)
Real-time:   3:18PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.32 - 0.39
52 week 0.32 - 1.32
Open 0.38
Vol / Avg. 81,849.00/111,903.00
Mkt cap 32.56M
P/E     -
Div/yield     -
EPS -0.22
Shares 88.96M
Beta 1.34
Inst. own 55%
Nov 2, 2015
Q1 2016 Cardica Inc Earnings Release (Estimated) Add to calendar
Aug 11, 2015
Cardica Inc at Wedbush PacGrow Healthcare Conference
Aug 6, 2015
Q4 2015 Cardica Inc Earnings Call - Webcast
Aug 6, 2015
Q4 2015 Cardica Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2015
Net profit margin -549.36% -641.54%
Operating margin -536.38% -628.19%
EBITD margin - -628.19%
Return on average assets -49.35% -49.91%
Return on average equity -101.53% -85.14%
Employees 75 -
CDP Score - -


900 Saginaw Drive
United States - Map
+1-650-3649975 (Phone)
+1-650-3643134 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Cardica, Inc. is focused on the commercialization and development of microcutter product line intended for use by thoracic, bariatric, colorectal and general surgeons. The microcutter product line consists of the commercially-available MicroCutter XCHANGE 30 and products in development, including the MicroCutter XCHANGE 45, the MicroCutter FLEXCHANGE 30 and the MicroCutter XPRESS 45. The Company’s business focuses on the design, manufacture and marketing of automated anastomotic systems used by cardiac surgeons to perform coronary bypass surgery. Its C-Port Distal Anastomosis Systems, or C-Port systems, are sold in the United States and Europe. The C-Port systems are used to perform a distal anastomosis, which is the connection between a bypass graft vessel and the target coronary artery. The PAS-Port system is used to perform a proximal anastomosis, which is the connection of a bypass graft vessel to the aorta or other source of blood.

Officers and directors

Bernard A. Hausen M.D.,Ph.D. President, Chief Executive Officer, Chief Medical Officer, Director
Age: 53
Bio & Compensation  - Reuters
Robert Y. Newell IV Chief Financial Officer, Vice President - Finance
Age: 65
Bio & Compensation  - Reuters
Liam J Burns Vice President - Sales and Marketing
Bio & Compensation  - Reuters
William P. Moffitt III Independent Director
Bio & Compensation  - Reuters
Gary S. Petersmeyer Independent Director
Age: 68
Bio & Compensation  - Reuters
John G. Simon PhD Independent Director
Age: 41
Bio & Compensation  - Reuters
William H. Younger Jr Independent Director
Age: 65
Bio & Compensation  - Reuters